Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Halaven Fails to Meet Primary Endpoints vs Capecitabine in PIII Study: Eisai
July 11, 2012
- Suzuken to Offer Voluntary Early Retirement Program for Record 500 Employees
July 11, 2012
- BMKK Applies for Orencia SC Injection
July 11, 2012
- Takeda to Offer US Dollar Senior Notes for Repaying Debt for Nycomed Acquisition
July 11, 2012
- Taisho HD Acquires Mexican Pharmaceutical Companies to Enter OTC Drug Business
July 11, 2012
- Shionogi Launches First European Development Base
July 10, 2012
- Otsuka Licenses Digital Health Technology from Proteus of the US
July 10, 2012
- Astellas Launches RLS Treatment Regnite on July 10
July 10, 2012
- Pharmaceutical Companies Set Up Private Power Generators in Preparation for Planned Power Outages
July 9, 2012
- Ethical Drug Sales Up 9.7% in May, Pushed by 2 Extra Working Days: Crecon Report
July 9, 2012
- MTPC Launches Argatroban for HIT Type II in the UK
July 9, 2012
- Bayer Confident in Pipeline, Regards Japan as Strategically Important Country: Mr Fibig
July 6, 2012
- Takeda Completes Acquisition of Multilab, Mid-Sized Brazilian Pharm Company
July 5, 2012
- Zonegran Approved for Monotherapy in Europe: Eisai
July 5, 2012
- Nippon Kayaku Considers Promotional Measures for Biosimilars, Vascular Embolization Medical Devices
July 5, 2012
- AZ to Promote Symbicort, SMART Therapy Targeting GPs, Specialists
July 5, 2012
- Ono to Start PI Trial for Anticancer Vaccine Licensed from OncoTherapy
July 5, 2012
- Japan Becomes World No. 2 Vaccine Market Pushed by HPV Vaccines
July 4, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…